Cyclosporine-A reduces spontaneous place preference in adult rats

Neuroscience Letters

Volumn 267, Issue 3, 1999, Pages 169-172

  Borlongan, Cesario V ^a   Kwanbara, Yasuhiro ^b   Fujisaki, Tomoko ^b   Watanabe, Shigeru ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Aversive stimulus; Conditioning; Drug abuse; Immunosuppressant; Place preference; Reinforcing effect

Indexed keywords

CYCLOSPORIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERSION; BEHAVIOR; CONDITIONING; CONTROLLED STUDY; DOSE RESPONSE; LOCOMOTION; MALE; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; RAT; REINFORCEMENT;

ANIMALS; BEHAVIOR, ANIMAL; CONDITIONING (PSYCHOLOGY); CYCLOSPORINE; IMMUNOSUPPRESSIVE AGENTS; MALE; MOTOR ACTIVITY; RATS; RATS, WISTAR;

EID: 0033522978     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(99)00357-2     Document Type: Article

References (20)

1. Borlongan C.V., Freeman T.B., Hauser R.A., Cahill D.W., Sanberg P.R. Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: relevance to neural transplantation. Surg. Neurol. 46:1996;384-388.
2. Borlongan C.V., Freeman T.B., Scorcia T.A., Sherman K.A., Olanow W.C., Cahill D.W., Sanberg P.R. Cyclosporine-A increases spontaneous and dopamine agonist-induced locomotor behavior in normal rats. Cell Transplant. 4:1995;65-73.
3. Borlongan C.V., Fujisaki T., Watanabe S. Chronic administration of Cyclosporine-A does not impair memory retention in rats. NeuroReport. 8:1997;673-676.
4. Borlongan C.V., Stahl C.E., Cameron D., Saporta S., Freeman T.B., Cahill D.W., Sanberg P.R. CNS immunological modulation of neural graft rejection and survival. Neurol. Res. 18:1996;297-304.
5. Borlongan C.V., Stahl C.E., Fujisaki T., Sanberg P.R., Watanabe S. Cyclosporine-A-induced hyperactivity in rats: is it mediated by immunosuppression, neurotrophism or both? Cell Transplant. 1999;. in press.
6. Costantini L.C., Chaturvedi P., Armistead D.M., McCaffrey P.G., Deacon T.W., Isacson O. A novel immunophilin ligand: distinct branching effects on dopaminergic neurons in culture and neurotrophic actions after oral administration in an animal model of Parkinson's disease. Neurobiol. Dis. 5:1998;97-106.
7. Exton M.S., Von Horsten S., Voge J., Westermann J., Schult M., Nagel E., Schedlowski M. Conditioned taste aversion produced by cyclosporine A: concomitant reduction in lymphoid organ weight and splenocyte proliferation. Physiol. Behav. 63:1998;241-247.
8. Grochowicz P.M., Schedlowski M., Husband A.J., King M.G., Hibberd A.D., Bowen K.M. Behavioral conditioning prolongs heart allograft survival in rats. Brain Behav. Immunol. 5:1991;349-356.
9. Kamei J., Kawashima N., Suzuki T., Misawa M., Kasuya Y. The effects of cyclosporine on morphine-induced antinociception in diabetic mice. Neurosci. Lett. 158:1993;213-216.
10. Klosterhalfen S., Klosterhalfen W. Conditioned cyclosporine effects but not conditioned taste aversion in immunized rats. Behav. Neurosci. 104:1991;716-724.
11. Matsuura K., Kabuto H., Makino H., Ogawa N. Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain. Brain Res. 733:1996;101-104.
12. Matsuura K., Makino H., Ogawa N. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine. Exp. Neurol. 146:1997;526-535.
13. Racusen L., Famiglio L., Fivush B., Olton D.S., Solez K. Neurologic abnormalities and mortality in rats treated with cyclospoline A. Transplant. Proc. 3:1988;934-936.
14. Schinkel A.H., Wagenaar E., van Deemter L., Mol C.A., Borst P. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 96:1995;1698-1705.
15. Steiner J.P., Connolly M.A., Valentine H.L., Hamilton G.S., Dawson T.M., Hester L., Snyder S.H. Neurotrophic actions of nonimmunosuppressive analogues of immunosuppressive drugs FK506, rapamycin and cyclosporin A. Nat. Med. 3:1997;421-428.
16. Suzuki T., Yoshiike M., Funada M., Mizoguchi H., Kamei J., Misawa M. Effect of cyclosporine A on the morphine-induced place preference. Neurosci. Lett. 160:1993;159-162.
17. Uchino H., Elmer E., Uchino K., Li P.A., He Q.P., Smith M.L., Siesjo B.K. Amelioration by cyclosporin A of brain damage in transient forebrain ischemia in the rat. Brain Res. 812:1998;216-226.
18. von Horsten S., Exton M.S., Schult M., Nagel E., Stalp M., Schweitzer G., Voge J., del Rey A., Schedlowski M., Westermann J. Behaviorally conditioned effects of Cyclosporine A on the immune system of rats: specific alterations of blood leukocyte numbers and decrease of granulocyte function. J. Neuroimmunol. 85:1998;193-201.
19. Weinbrenner C., Liu G.S., Downey J.M., Cohen M.V. Cyclosporine A limits myocardial infarct size even when administered after onset of ischemia. Cardiovasc. Res. 38:1998;678-684.
20. Yue Q.Y., Säwe J. Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur. J. Clin. Pharmacol. 52:1997;41-47.